You just read:

Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma

News provided by

Merrimack Pharmaceuticals, Inc.

Mar 24, 2016, 07:00 ET